ID: ALA568373

Max Phase: Preclinical

Molecular Formula: C25H50NO9P

Molecular Weight: 539.65

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC

Standard InChI:  InChI=1S/C25H50NO9P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24(27)33-19-22(32-2)20-34-36(30,31)35-21-23(26)25(28)29/h22-23H,3-21,26H2,1-2H3,(H,28,29)(H,30,31)/t22-,23-/m0/s1

Standard InChI Key:  RIWHHKIQQIRFCQ-GOTSBHOMSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 539.65

Molecular Weight (Monoisotopic): 539.3223

AlogP: 5.35

#Rotatable Bonds: 26

Polar Surface Area: 154.61

Molecular Species: ZWITTERION

HBA: 8

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 1.44

CX Basic pKa: 9.38

CX LogP: 4.08

CX LogD: 1.12

Aromatic Rings: 0

Heavy Atoms: 36

QED Weighted: 0.07

Np Likeness Score: 0.84

References

1. Iwashita M, Makide K, Nonomura T, Misumi Y, Otani Y, Ishida M, Taguchi R, Tsujimoto M, Aoki J, Arai H, Ohwada T..  (2009)  Synthesis and evaluation of lysophosphatidylserine analogues as inducers of mast cell degranulation. Potent activities of lysophosphatidylthreonine and its 2-deoxy derivative.,  52  (19): [PMID:19743861] [10.1021/jm900598m]

Source

Source(1):

• Scientific Literature